EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Current landscape of cystic fibrosis gene therapy

Lindsey W Plasschaert, Kelvin D MacDonald, Jeffrey S Moffit

Frontiers in Pharmacology · 08.10.2024 · 15

DOI: 10.3389/fphar.2024.1476331 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Frontiers in Pharmacology, online erschienen am 08.10.2024. Verfasst von Lindsey W Plasschaert und 2 weiteren Autor:innen. Beteiligte Einrichtung: Plasschaert Consulting, Cambridge, MA, United States. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 117 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cystic fibrosis is a life-threatening disease that is caused by mutations in CFTR , a gene which encodes an ion channel that supports proper function of several epithelial tissues, most critically the lung. Without CFTR, airway barrier mechanisms are impaired, allowing for chronic, recurrent infections that result in airway remodeling and deterioration of lung structure and function. Small molecule modulators can rescue existing, defective CFTR protein; however, they still leave a subset of people with CF with no current disease modifying treatments, aside from lung transplantation. Gene therapy directed to the lung is a promising strategy to modify CF disease in the organ most associated with morbidity and mortality. It is accomplished through delivery of a CFTR transgene with an airway permissive vector. Despite more than three decades of research in this area, a lung directed gene therapy has yet to be realized. There is hope that with improved delivery vectors, sufficient transduction of airway cells can achieve therapeutic levels of functional CFTR. In order to do this, preclinical programs need to meet a certain level of CFTR protein expression in vitro and in vivo through improved transduction, particularly in relevant airway cell types. Furthermore, clinical programs must be designed with sensitive methods to detect CFTR expression and function as well as methods to measure meaningful endpoints for lung structure, function and disease. Here, we discuss the current understanding of how much and where CFTR needs to be expressed, the most advanced vectors for CFTR delivery and clinical considerations for detecting CFTR protein and function in different patient subsets.

Schlagwörter

Stichwörter der Autor:innen

CFTRairwaycystic fibrosisgene therapytransductionviral vector

Autor:innen und Institutionen

  • Plasschaert Consulting, Cambridge, MA, United States.
  • Carbon Biosciences, Waltham, MA, United States.
  • Department of Pediatrics, Oregon Health and Science University, Portland, OR, United States.

Zitieren

APA

Plasschaert, L. W., MacDonald, K. D., & Moffit, J. S. (2024). Current landscape of cystic fibrosis gene therapy. Frontiers in Pharmacology, 15. https://doi.org/10.3389/fphar.2024.1476331

Vancouver

Plasschaert LW, MacDonald KD, Moffit JS. Current landscape of cystic fibrosis gene therapy. Frontiers in Pharmacology. 2024;15. doi:10.3389/fphar.2024.1476331

BibTeX
@article{Plasschaert2024,
  author = {Plasschaert, Lindsey W and MacDonald, Kelvin D and Moffit, Jeffrey S},
  title = {Current landscape of cystic fibrosis gene therapy},
  journal = {Frontiers in Pharmacology},
  year = {2024},
  volume = {15},
  doi = {10.3389/fphar.2024.1476331}
}
Kostenlos starten →